| HUMAN SERVICES Patent applications |
| Patent application number | Title | Published |
|---|
| 20120076817 | POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES - Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products. | 03-29-2012 |
| 20110259666 | SOUND ATTENUATION CANOPY - A sound attenuation canopy for reducing levels of sound passing through an opening comprises a sound absorbing member. The sound absorbing member is comprised of a flexible sound absorbing material and has a first end, a second end and an intermediate portion extending between the first end and the second end. The first end is configured to attach to a periphery of the opening at a first location, the second end is configured to attach to a periphery of the opening at a second location and the intermediate portion is configured to be spaced apart from the opening. When the first end and the second end of the sound absorbing member are attached to the periphery of the opening, at least one side opening is at least partially defined by the intermediate portion and the perimeter of the opening, and a sound transmission flow path through open space between the opening and the side opening comprises at least one change of direction greater than 45 degrees. | 10-27-2011 |
| 20110237666 | HYDROXYBUTYRATE ESTER AND MEDICAL USE THEREOF - A compound which is 3-hydroxybutyl 3-hydroxybutyrate enantiomerically enriched with respect to (3R)-hydroxybutyl (3R)-hydroxybutyrate of formula (I) is an effective and palatable precursor to the ketone body (3R)-hydroxybutyrate and may therefore be used to treat a condition which is caused by, exacerbated by or associated with elevated plasma levels of free fatty acids in a human or animal subject, for instance a condition where weight loss or weight gain is implicated, or to promote alertness or improve cognitive function, or to treat, prevent or reduce the effects of neurodegeneration, free radical toxicity, hypoxic conditions or hyperglycaemia. | 09-29-2011 |
| 20110189193 | CELL LINES AND HOST NUCLEIC ACID SEQUENCES RELATED TO INFECTIOUS DISEASE - Host nucleic acids and host proteins that participate in viral infection, such as human immunodeficiency virus (HIV), influenza A, and Ebola virus, have been identified. Interfering with or disrupting the interaction between a host nucleic acid or host protein and a virus or viral protein confers an inhibition of or resistance to infection. Thus, interfering with such an interaction in a host subject can confer a therapeutic or prophylactic effect against a virus. The sequences identified can be used to identify agents that reduce or inhibit viral infection. | 08-04-2011 |
| 20110152355 | METHOD FOR PREDICTING AND DETECTING TUMOR METASTASIS - The invention provides a method of determining the prognosis of cancer in a subject. The method comprises (a) obtaining a sample from the subject, (b) analyzing the sample for the expression level of a carboxypeptidase E (CPE) splice variant, and (c) correlating the expression level in the sample with the prognosis of cancer in the subject. The invention further provides a method of diagnosing cancer, methods of treatment, kits for detecting mRNA expression of a CPE-ΔN, and inhibitors of CPE-ΔN and compositions thereof. | 06-23-2011 |
| 20110152115 | METHODS FOR IDENTIFYING, DIAGNOSING, AND PREDICTING SURVIVAL OF LYMPHOMAS - The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information is useful in developing the appropriate therapeutic approach for use with a particular subject. | 06-23-2011 |
| 20110117101 | CC CHEMOKINE RECEPTOR 5 DNA, NEW ANIMAL MODELS AND THERAPEUTIC AGENTS FOR HIV INFECTION - The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV. | 05-19-2011 |
| 20110027299 | MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC METHODS - The present invention provides an isolated or purified immunogenic peptide comprising 8-15 contiguous amino acids of gp100 (SEQ ID NO: 121) and related nucleic acids, expression vectors, host cells, populations of cells, and methods of use. The invention further provides immunogenic peptides derived from gp100 which have been modified to enhance their immunogenicity and related nucleic acids, expression vectors, host cells, populations of cells, and methods of use. | 02-03-2011 |
| 20100267712 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES - Disclosed is a compound of Formula (I) in which W and R | 10-21-2010 |
| 20100255491 | MAMMALIAN SELENOPROTEIN DIFFERENTIALLY EXPRESSED IN TUMOR CELLS - A 15 kDa selenium-containing protein (“selenoprotein”) is disclosed. The protein is shown to be differentially expressed in cancer cells, such as prostate cancer cells. There is a correlation between the presence of a polymorphism at nucleotide positions 811 and 1125 of the 15 kDa selenoprotein gene, and the presence of cancer. This polymorphism is more prevalent in the African American population. The determination of an individual's genotype may be used as an indicator of the need for dietary selenium supplementation to inhibit tumor development. Compositions including the isolated protein, specific binding agents that recognize the protein, as well as underlying nucleic acid sequences are presented, as are methods of using such compositions. | 10-07-2010 |
| 20100254898 | ANTIBODIES THAT BIND GalNAc1-3Gal, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME - Monoclonal antibodies to carbohydrate antigens containing a terminal GalNAcα1-3Gal are provided. The antibodies of the present invention are found to specifically recognize GalNAcα1-3Gal with little cross-reactivity to other structurally similar antigens such as GalNAcα1-6Gal, blood group A, Forssman antigen and the Tn antigen on both solution assays and human tissue. Compositions comprising the monoclonal antibodies, as well as methods of diagnosis, treatment and prognostication are also provided. | 10-07-2010 |
| 20090326054 | COMPOSITIONS AND METHODS FOR INHIBITING TRANSLATION OF A MECT1-MAML2 CHIMERIC GENE - Composition for the inhibition of the translation of a Mect1-MAML2 chimeric gene consisting essentially of: (a) a fragment of the nucleic acid encoding the chimeric gene, and (b) a nucleic acid complementary to the fragment, and a method of inhibiting the translation of a Mect1-MAML2 chimeric gene comprising contacting a cell expressing the chimeric gene with the composition, whereupon the translation of the chimeric gene is inhibited. | 12-31-2009 |
| 20090136952 | MANGANESE SUPEROXIDE DISMUTASE VAL16ALA POLYMORPHISM PREDICTS RESISTANCE TO CHEMOTHERAPEUTIC DRUG CANCER THERAPY - The present invention provides, for the first time, the finding that the manganese superoxide dismutase Val16Ala polymorphism is significantly associated with prognosis for cancer patients treated with chemotherapeutic drug therapy. The alanine allele is a novel biomarker that predicts poor response and poor outcome to chemotherapeutic drug cancer therapy. Conversely, the valine allele predicts a good response and a good outcome to chemotherapeutic drug cancer therapy. Therefore, a genotype assay can be used to determine which alleles a subject is carrying, and subsequently this information can be used to determine if chemotherapeutic drug therapy is appropriate, and to customize therapy according to the patient's MnSOD genotype. | 05-28-2009 |
| 20080207504 | SECRETED FRIZZLED RELATED PROTEIN, sFRP, FRAGMENTS AND METHODS OF USE THEREOF - The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt proteins and modulate Wnt biological activity. Accordingly, the invention provides these sFRP fragments and variants of these fragments, as well as vectors and host cells containing nucleic acid sequences encoding the sFRP fragments and variants. | 08-28-2008 |
